- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03761784
A Study of S6G5T-3 in the Treatment of Acne Vulgaris
December 14, 2021 updated by: Sol-Gel Technologies, Ltd.
A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S6G5T-3 in the Treatment of Acne Vulgaris
To assess the efficacy of S6G5T-3 compared to its Vehicle when applied once daily for 12 weeks in participants with acne vulgaris.
Study Overview
Detailed Description
In this Phase 3, multi-center, double-blind, randomized, vehicle-controlled, parallel-group pivotal study, participants will be admitted only after a written informed consent has been obtained and after all inclusion/exclusion criteria have been met.
Male and female participants at least 9 years of age with facial acne vulgaris will be eligible for enrollment for daily treatment with S6G5T-3 or its vehicle S6G5T-8, for 12 weeks.
Study Type
Interventional
Enrollment (Actual)
424
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
High Point, North Carolina, United States, 27262
- Dermatology Consulting Services
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
9 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participant must sign an Institutional Review Board (IRB) approved written informed consent for this study.
- Male and female 9 years of age and older.
- Have 2 or fewer cysts or nodules.
Exclusion Criteria:
- More than 2 acne nodules or cysts (defined as an inflammatory lesion greater than or equal to 5 millimeter (mm) in diameter).
- Acne conglobata, acne fulminans, and secondary acne (for example, chloracne, drug-induced acne).
- History of blood dyscrasia (for example, leukemia, haemophilia, sickle cell anemia, multiple myeloma).
- Underlying disease that requires the use of interfering topical or systemic therapy.
- Other dermatological conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments such as, but not limited to, atopic dermatitis, perioral dermatitis, or rosacea.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: S6G5T-3
Participants will topically apply S6G5T-3 cream, once daily to face for 12 weeks.
|
Once a day topical cream
Other Names:
|
Placebo Comparator: S6G5T-8 Vehicle Cream
Participants will topically apply S6G5T-8 vehicle cream, once daily to face for 12 weeks.
|
Once a day topical cream
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving an IGA Score of Clear or Almost Clear and a Score ≥2 Grades Less Than Baseline
Time Frame: Baseline through Week 12
|
Percentage of participants in each treatment group achieving an acne severity IGA score of "clear (score=0)" or "almost clear (score=1)" and achieving an acne severity IGA score of at least 2 grades less than Baseline.
|
Baseline through Week 12
|
Change From Baseline in Inflammatory Lesion Counts on the Face at Week 12
Time Frame: Baseline, Week 12
|
Inflammatory lesions were characterized by papules, pustules, nodules, and cysts.
Least squares means and standard deviations from an analysis of covariance (ANCOVA) with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate.
For the inflammatory lesion count analysis, the interaction of treatment by analysis center was included in the model based on the conclusion from the pooling analysis.
Negative least squares means values represent decrease from Baseline.
|
Baseline, Week 12
|
Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 12
Time Frame: Baseline, Week 12
|
Non-inflammatory lesions were characterized by open comedones (blackheads) and closed comedones (whiteheads).
Least squares means and standard deviations from an ANCOVA with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate.
Negative least squares means values represent decrease from Baseline.
|
Baseline, Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 12
Time Frame: Baseline, Week 12
|
Non-inflammatory lesions were characterized by open comedones (blackheads) and closed comedones (whiteheads).
Least squares means and standard deviations from an ANCOVA with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate.
Negative least squares means values represent decrease from Baseline.
|
Baseline, Week 12
|
Percent Change From Baseline in Inflammatory Lesion Counts on the Face at Week 12
Time Frame: Baseline, Week 12
|
Inflammatory lesions were characterized by papules, pustules, nodules, and cysts.
Least squares means and standard deviations from an ANCOVA with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate.
For the inflammatory lesion count analysis, the interaction of treatment by analysis center was included in the model based on the conclusion from the pooling analysis.
Negative least squares means values represent decrease from Baseline.
|
Baseline, Week 12
|
Percentage of Participants Achieving at Least a 4-Point Reduction on Item 1 (Pimple) of the Patient-Reported Evaluation of Facial Acne (Pre-Face)
Time Frame: Baseline and Week 12
|
Percent of participants in each treatment group achieving at least a 4-point reduction on Item 1 (Pimple) of patient-reported evaluation of facial acne compared to Baseline.
The Pre-Face is a 7-item questionnaire that assesses acne vulgaris-related signs, symptoms, and impacts.
Item 1 of the questionnaire was to assess the pimples on the participant's face at their worst, in the 24 hours prior to administration on an 11-point numeric rating scale (NRS) ranging from 0 ("no pimples at all") to 10 ("pimples as bad as you can imagine").
|
Baseline and Week 12
|
Percentage of Participants Achieving at Least a 4-Point Reduction on Item 5 (Embarrassment) of the Pre-Face
Time Frame: Baseline and Week 12
|
Percent of participants in each treatment group achieving at least a 4-point reduction on Item 5 (Embarrassment) of the patient-reported evaluation of facial acne compared to Baseline.
The Pre-Face is a 7-item questionnaire that assesses acne vulgaris-related signs, symptoms, and impacts.
Item 5 of the questionnaire was to assess how embarrassed the participant felt because of the acne at their worst in the 24 hours prior to administration on an 11-point NRS ranging from 0 ("not embarrassed at all") to 10 ("extremely embarrassed").
|
Baseline and Week 12
|
Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 8
Time Frame: Baseline, Week 8
|
Non-inflammatory lesions were characterized by open comedones (blackheads) and closed comedones (whiteheads).
Least squares means and standard deviations from an ANCOVA with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate.
Negative least squares means values represent decrease from Baseline.
|
Baseline, Week 8
|
Change From Baseline in Inflammatory Lesion Counts on the Face at Week 8
Time Frame: Baseline, Week 8
|
Inflammatory lesions were characterized by papules, pustules, nodules, and cysts.
Least squares means and standard deviations from an ANCOVA with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate.
For the inflammatory lesion count analysis, the interaction of treatment by analysis center was included in the model based on the conclusion from the pooling analysis.
Negative least squares means values represent decrease from Baseline.
|
Baseline, Week 8
|
Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 4
Time Frame: Baseline, Week 4
|
Non-inflammatory lesions were characterized by open comedones (blackheads) and closed comedones (whiteheads).
Least squares means and standard deviations from an ANCOVA with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate.
Negative least squares means values represent decrease from Baseline.
|
Baseline, Week 4
|
Change From Baseline in Inflammatory Lesion Counts on the Face at Week 4
Time Frame: Baseline, Week 4
|
Inflammatory lesions were characterized by papules, pustules, nodules, and cysts.
Least squares means and standard deviations from an ANCOVA with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate.
For the inflammatory lesion count analysis, the interaction of treatment by analysis center was included in the model based on the conclusion from the pooling analysis.
Negative least squares means values represent decrease from Baseline.
|
Baseline, Week 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 21, 2018
Primary Completion (Actual)
December 31, 2019
Study Completion (Actual)
December 31, 2019
Study Registration Dates
First Submitted
November 30, 2018
First Submitted That Met QC Criteria
November 30, 2018
First Posted (Actual)
December 3, 2018
Study Record Updates
Last Update Posted (Actual)
December 16, 2021
Last Update Submitted That Met QC Criteria
December 14, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SGT-65-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Vulgaris
-
Galderma R&DCompletedSevere Acne VulgarisUnited States, Canada, Puerto Rico
-
Sebacia, Inc.CompletedInflammatory Acne VulgarisUnited States
-
Nexgen Dermatologics, Inc.Unknown
-
Rejuva Medical AestheticsHealMD, LLCNot yet recruitingAcne Vulgaris (Disorder)United States
-
InMode MD Ltd.Active, not recruitingInflammatory Acne VulgarisUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingModerate to Severe Acne VulgarisChina
-
PollogenLumenis Be Ltd.RecruitingModerate to Severe Acne VulgarisUnited States
-
Boston PharmaceuticalsCompletedModerate to Severe Acne VulgarisUnited States, Canada
-
Bispebjerg HospitalCompleted
-
Actavis Mid-Atlantic LLCCompletedMILD TO SEVERE ACNE VULGARISIndia
Clinical Trials on S6G5T-3
-
Sol-Gel Technologies, Ltd.AccelovanceCompletedAcne VulgarisUnited States
-
Sol-Gel Technologies, Ltd.Completed
-
Sol-Gel Technologies, Ltd.CompletedAcne VulgarisUnited States
-
Eastern Mediterranean UniversityCompletedOverweight and ObesityCyprus
-
Edwards LifesciencesActive, not recruitingHeart Diseases | Aortic Stenosis, SevereUnited States, Canada
-
Third Affiliated Hospital, Sun Yat-Sen UniversityUnknown
-
Edwards LifesciencesActive, not recruitingAortic Valve Stenosis | Aortic Stenosis, CalcificUnited States, Australia, Japan, Canada, Netherlands, Switzerland
-
University of AarhusSteno Diabetes Center Aarhus, Aarhus University Hospital, Denmark; Department...CompletedKetosis | Postprandial Hyperglycemia | Glucose Metabolism Disorders (Including Diabetes Mellitus)Denmark
-
Edwards LifesciencesRecruitingPulmonary Valve Insufficiency | Complex Congenital Heart Defect | Dysfunctional RVOT Conduit | Pulmonary Valve DegenerationUnited States
-
Sheffield Children's NHS Foundation TrustUniversity of SheffieldCompletedAcute BronchiolitisUnited Kingdom